Curanosticum operates a theranostics platform that combines molecular imaging and radiomolecular therapies for personalized cancer treatment, utilizing advanced PET-CT technology and radioactively labeled substances. The platform addresses the need for precise diagnostics and targeted therapies, improving patient outcomes and quality of life in oncology care.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer treatment often lacks precision, leading to potential harm to healthy tissues and incomplete eradication of cancerous cells. Accurate diagnostics and targeted therapies are needed to improve patient outcomes and quality of life in oncology.
Solution
Curanosticum operates a theranostics platform that integrates advanced molecular imaging with radiomolecular therapies to deliver personalized cancer treatment. Utilizing state-of-the-art PET-CT technology and radioactively labeled substances, Curanosticum enables precise diagnostics and targeted therapy. The platform offers comprehensive molecular imaging for cancer diagnostics and radiomolecular cancer treatment from a single source. By combining diagnostic imaging and targeted radionuclide therapies, Curanosticum aims to optimize treatment efficacy while minimizing side effects.
Target Audience
Curanosticum serves oncology patients requiring precise diagnostics and targeted radiomolecular therapies, as well as referring physicians and clinical partners seeking advanced imaging and treatment options.
Features
- Advanced PET-CT imaging for tumor and inflammation diagnostics
- Radioligand therapy (PSMA) for prostate cancer
- Radioreceptor therapy (DOTATOC) for neuroendocrine tumors
- Radioiodine therapy for thyroid disorders
- Scintigraphy for various organs (heart, bone, lung, kidney, brain, parathyroid, salivary glands, sentinel lymph nodes)
- Comprehensive thyroid diagnostics and therapy